A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Verstovšek, Srđan; A. Mesa, Ruben; Gotlib, Jason; S. Levy, Richard; Gupta, Vikas; F. DiPersio, John; Catalano, John; W. Deininger, Michael; B. Miller, Carole; T. Silver, Richard; Talpaz, Moshe; F. Winton, Elliott; H. Harvey, Jimmie; O. Arcasoy, Murat; O. Hexner, Elizabeth; M. Lyons, Roger; Paquette, Ronald; Raza, Azra; Vaddi, Kris; Erickson‐Viitanen, Susan; L. Koumenis, Iphigenia; Sun, William; Sandor, Victor; M. Kantarjian, Hagop

doi:10.1056/nejmoa1110557

Public

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Published in New England Journal of Medicine • Feb 29, 2012

Authors:

Srđan Verstovšek

Ruben A. Mesa

Jason Gotlib

Abstract

BACKGROUND: Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis. METHODS: In this double-blind trial, we randomly assigned patients with intermediate-2 or high-risk myelofibrosis to twice-daily oral ruxolitinib (155 patients) or plac...

Subject

Ruxolitinib

Myelofibrosis

Janus kinase inhibitor

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!